3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Breast
2
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Colorectal Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Hyperlipoproteinemia Type II
1
Head and Neck Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colitis, Ulcerative
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
pembrolizumab
50
Cyclophosphamide
25
Carboplatin
25
Gemcitabine
20
Cisplatin
19
fludarabine
18
Nivolumab
17
Paclitaxel
16
Bevacizumab
15
Specimen Handling
14
Fluorouracil
11
Magnetic Resonance Spectroscopy
10
aldesleukin
9
Oxaliplatin
9
Irinotecan
9
Docetaxel
9
Biopsy
9
olaparib
8
Trastuzumab
8
durvalumab
7
atezolizumab
7
Hyperthermic Intraperitoneal Chemotherapy
7
Albumin-Bound Paclitaxel
7
Taxes
6
Leucovorin
6
Ipilimumab
6
Interleukin-2
6
Cetuximab
6
Capecitabine
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Atorvastatin
×
Gastrointestinal
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn